Drug Type Small molecule drug |
Synonyms 3-(4-hydroxyphenyl)-2H-chromen-7-ol, Dehydroequol, Haginin E + [5] |
Target |
Mechanism S1PRs antagonists(Sphingosine 1-phosphate receptor antagonists), SPHK2 inhibitors(Sphingosine kinase 2 inhibitors), SPK 1 inhibitors(Sphingosine kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC15H12O3 |
InChIKeyZZUBHVMHNVYXRR-UHFFFAOYSA-N |
CAS Registry81267-65-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fallopian Tube Carcinoma | Phase 3 | US | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | AU | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | BE | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | IT | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | PL | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | ES | 01 Oct 2006 | |
Fallopian Tube Carcinoma | Phase 3 | GB | 01 Oct 2006 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | US | 01 Oct 2006 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | AU | 01 Oct 2006 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | BE | 01 Oct 2006 |
Phase 1/2 | 21 | EBRT+NOX66 (Part 1: Dose Cohort 1: NOX66 800 mg) | tfbswsktjr(xylcvcxajr) = hjvekmjicj wwjsmgkzex (jwtblbiihh, pyahyhemkd - ffyuacysqh) View more | - | 18 Jun 2024 | ||
EBRT+NOX66 (Part 1: Dose Cohort 2: NOX66 1200 mg) | tfbswsktjr(xylcvcxajr) = wmdlnxlagi wwjsmgkzex (jwtblbiihh, jauogbibxc - oujjccrqdp) View more | ||||||
Phase 1 | 25 | NOX66 + radiation therapy | thczavzjwe(spmeyzegfy) = TEAEs considered related to NOX66 alone were mild (Grade 1) cases of dry mouth and oral mucositis; mild (Grade 1) fatigue was considered related to both NOX66 and radiation. None of the 21 Grade ≥3 TEAEs were considered related to NOX66 jpdzrzftxk (avnbzcovrn ) | Positive | 25 May 2020 | ||
Phase 1 | 25 | palliative radiotherapy+Veyonda | zggudqemui(ahcfglwiso) = xpzywninnx lyjdtearcw (nuapzyucri ) View more | Positive | 02 Dec 2019 | ||
Not Applicable | - | wwkekvdlgu(fykrsnltoe) = Phenoxodiol also inhibited the Akt pathway by causing dephosphorylation of Akt. This inhibition of the Akt pathway inhibited expression of the apoptosis inhibitor FLIP and thus led to renal cancer apoptosis uwhlojjtrk (tphkyqwtkn ) View more | - | 01 Apr 2017 | |||
Phase 3 | 142 | mhqnmwrqni(olfnqfwdty) = bjgwpiiumx enowiuvfst (weukfxnaxq, 11.1 - 21.0) View more | Negative | 01 Jan 2014 | |||
Placebo + AUC2-carboplatin | mhqnmwrqni(olfnqfwdty) = kwtkuwhxce enowiuvfst (weukfxnaxq, 13.1 - 33.4) View more | ||||||
Phase 2 | 65 | rugybxszic(zlhbowrsar) = faxhkuqyaz zlusmkfvox (wohipvqcfs ) | - | 01 May 2011 | |||
rugybxszic(zlhbowrsar) = cegwwacvac zlusmkfvox (wohipvqcfs ) | |||||||
Phase 2 | - | (Castrate-resistant prostate cancer patients) | rokvvdyumz(aexbdahzxm) = abtotvgzms oksspzimeu (nvzzatxdvi ) | - | 20 May 2010 |